NZ596244A - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases

Info

Publication number
NZ596244A
NZ596244A NZ596244A NZ59624407A NZ596244A NZ 596244 A NZ596244 A NZ 596244A NZ 596244 A NZ596244 A NZ 596244A NZ 59624407 A NZ59624407 A NZ 59624407A NZ 596244 A NZ596244 A NZ 596244A
Authority
NZ
New Zealand
Prior art keywords
cell
treatment
neurodegenerative diseases
selenate
vitro
Prior art date
Application number
NZ596244A
Other languages
English (en)
Inventor
Christopher Hovens
Niall Corcoran
Original Assignee
Velacor Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velacor Therapeutics Pty Ltd filed Critical Velacor Therapeutics Pty Ltd
Publication of NZ596244A publication Critical patent/NZ596244A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NZ596244A 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases NZ596244A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
NZ596244A true NZ596244A (en) 2013-05-31

Family

ID=38540722

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596244A NZ596244A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases
NZ571835A NZ571835A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ571835A NZ571835A (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (2) US8920851B2 (enExample)
EP (1) EP2004204B1 (enExample)
JP (1) JP5542430B2 (enExample)
KR (1) KR101451439B1 (enExample)
CN (1) CN101478977B (enExample)
AU (1) AU2007231547B2 (enExample)
BR (1) BRPI0709033A2 (enExample)
CA (1) CA2644441C (enExample)
DK (1) DK2004204T3 (enExample)
ES (1) ES2394348T3 (enExample)
MX (1) MX2008012479A (enExample)
NZ (2) NZ596244A (enExample)
RU (1) RU2489155C2 (enExample)
WO (1) WO2007109851A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578226B1 (en) 2004-08-23 2017-10-25 Yeda Research And Development Co., Ltd. Peptide for treating amyotrophic lateral sclerosis
WO2007109851A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
CA2650309C (en) * 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
JP2011504474A (ja) * 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
US20110130466A1 (en) * 2009-10-09 2011-06-02 Stefan Lorenzl Use of rasagiline for the treatment of progressive supranuclear palsy
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
CN106794222B (zh) * 2015-03-26 2021-08-24 苏州澳宗生物科技有限公司 使用p75ecd和/或p75诊断或治疗神经障碍的方法
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
CN112654367B (zh) * 2018-06-29 2023-08-04 再青春生物医药公司 用于年龄相关性和/或变性疾病的药物组合
CN114206214A (zh) 2019-03-26 2022-03-18 禧尔公司 用于生物流体的蛋白质冕分析的组合物、方法和系统及其用途
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
JPH04247033A (ja) * 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
US5695752A (en) * 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) * 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) * 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
JP2006525329A (ja) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸類
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) * 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
TWI319708B (en) 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US20080004255A1 (en) * 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
AU2007231549A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors
WO2007109851A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
RU2489155C2 (ru) 2013-08-10
EP2004204A1 (en) 2008-12-24
BRPI0709033A2 (pt) 2011-06-21
WO2007109851A1 (en) 2007-10-04
CN101478977B (zh) 2013-03-27
EP2004204A4 (en) 2010-06-02
US20090169649A1 (en) 2009-07-02
AU2007231547A1 (en) 2007-10-04
NZ571835A (en) 2011-11-25
EP2004204B1 (en) 2012-09-12
CA2644441A1 (en) 2007-10-04
KR101451439B1 (ko) 2014-10-16
RU2008142514A (ru) 2010-05-10
MX2008012479A (es) 2009-08-13
JP2009532340A (ja) 2009-09-10
CA2644441C (en) 2014-09-09
JP5542430B2 (ja) 2014-07-09
CN101478977A (zh) 2009-07-08
DK2004204T3 (da) 2013-01-07
US8920851B2 (en) 2014-12-30
ES2394348T3 (es) 2013-01-30
AU2007231547B2 (en) 2012-07-12
KR20090015038A (ko) 2009-02-11
US20140141104A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
NZ596244A (en) Treatment of neurodegenerative diseases
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
AU2007257423A8 (en) Purine analogs
MX374396B (es) Rocio de fentanilo sublingual.
MX2010004074A (es) Combinacion 059.
PH12012500382A1 (en) Heterocyclic compounds for the inhibition of pask
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
WO2009031606A1 (ja) 関節炎治療及び予防剤
MX2007005649A (es) Carboxiamidas de azaindol.
WO2007131232A3 (en) Compositions and their uses directed to ptpr alpha
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
CA2837895C (en) Methods of treating or preventing neurological diseases
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
SG195170A1 (en) Methods of treating or preventing rheumatic disease
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2008011473A3 (en) Compositions and their uses directed to hbxip
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2007025229A3 (en) Compositions and their uses directed to hsp27
ATE462430T1 (de) Pharmazeutische zusammensetzung zur behandlung von inkontinenz
DE602005001918D1 (de) S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 29/03/2007; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 29/03/2007

Effective date: 20130506

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 MAR 2014 BY DAVIES COLLISON CAVE

Effective date: 20130904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 MAR 2017 BY CPA GLOBAL

Effective date: 20140403

LAPS Patent lapsed